Bill > A05562

This bill establishes strict regulations for pharmacists when dealing with anti-epileptic drugs, specifically prohibiting any drug substitution without explicit notification and signed informed consent from both the prescribing physician and the patient (or the patient's parent, legal guardian, or spouse). The bill provides detailed definitions for key terms, including "anti-epileptic drug" (which covers drugs used to treat epilepsy or prevent seizures), "epilepsy" (a neurological condition characterized by recurrent seizures), and "interchange" (the substitution of different versions of anti-epileptic medications). By defining "interchange" broadly, the bill covers various potential drug substitutions, such as switching between brand and generic versions, different manufacturers' generic versions, or different formulations of the same drug. The legislation amends both the public health law and education law, effectively creating a special protection for patients with epilepsy by ensuring they and their physicians have full control and awareness of any potential medication changes. This approach recognizes the potentially sensitive nature of anti-epileptic medication management and the importance of maintaining consistent treatment for patients with seizure disorders.

Education

https://www.nysenate.gov/legislation/bills/2025/A5562